prikaz prve stranice dokumenta Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases
  Preuzmi
PDF 412.63 KB
Znanstveni rad - Izvorni znanstveni rad
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases
Croatian medical journal, 62 (2021), 5; 455-463. https://doi.org/10.3325/cmj.2021.62.455-63
Bašić-Kinda, Sandra; Mišura Jakobac, Karla; Sinčić-Petričević, Jasminka; Deak, Dajana; Vodanović, Marijo; Jakić-Bubalo, Marinka; Mitrović, Zdravko; Grubešić, Aron; Dreta, Barbara; Županić Krmek, Dubravka; Coha, Božena; Radić-Krišto, Delfa; Aurer, Igor

Citirajte ovaj rad

Bašić Kinda, S., Mišura Jakobac, K., Sinčić Petričević, J., Deak, D., Vodanović, M., Jakić Bubalo, M. ... Aurer, I. (2021). Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases. Croatian medical journal, 62. (5), 455-463. doi: 10.3325/cmj.2021.62.455-63

Bašić Kinda, Sandra, et al. "Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases." Croatian medical journal, vol. 62, br. 5, 2021, str. 455-463. https://doi.org/10.3325/cmj.2021.62.455-63

Bašić Kinda, Sandra, Karla Mišura Jakobac, Jasminka Sinčić Petričević, Dajana Deak, Marijo Vodanović, Marinka Jakić Bubalo, Zdravko Mitrović, et al. "Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases." Croatian medical journal 62, br. 5 (2021): 455-463. https://doi.org/10.3325/cmj.2021.62.455-63

Bašić Kinda, S., et al. (2021) 'Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases', Croatian medical journal, 62(5), str. 455-463. doi: 10.3325/cmj.2021.62.455-63

Bašić Kinda S, Mišura Jakobac K, Sinčić Petričević J, Deak D, Vodanović M, Jakić Bubalo M, i sur.. Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases. Croatian medical journal [Internet]. 2021. [pristupljeno 12.11.2024.];62(5):455-463. doi: 10.3325/cmj.2021.62.455-63

S. Bašić Kinda, et al., "Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases", Croatian medical journal, vol. 62, br. 5, str. 455-463, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:936669. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:936669
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non internventional study of the Croatian Cooperative Group for Hematologic Diseases
AutorSandra Bašić-Kinda
AutorKarla Mišura Jakobac
AutorJasminka Sinčić-Petričević
AutorDajana Deak
AutorMarijo Vodanović
AutorMarinka Jakić-Bubalo
AutorZdravko Mitrović
MBZ: 272370
AutorAron Grubešić
AutorBarbara Dreta
AutorDubravka Županić Krmek
MBZ: 228753
AutorBožena Coha
MBZ: 234601
AutorDelfa Radić-Krišto
MBZ: 243612
AutorIgor Aurer
MBZ: 165536
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Aim To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort). Methods The historical cohort consisted of 40 patients who started treatment with rituximab in 2007 and 2008. Data on the recent cohort, consisting of 89 patients, were collected retrospectively from the electronic databases of Croatian hospitals with hematology units. Demographic characteristics and data on induction regimens, autologous stem cell transplantation (ASCT), and rituximab maintenance in the first remission, event-free survival (EFS), and overall survival (OS) were available for both cohorts, and data on cell morphology, mantle cell international prognostic index (MIPI), and Ki67 expression only for the recent cohort. Results The recent cohort had significantly better two-year EFS and OS (EFS 58% vs 40%, P = 0.014 ; OS 80% vs 56%, P = 0.009), especially in patients below 65. In univariate analysis, induction regimen, ASCT, and maintenance were significant prognostic factors for EFS and the former two for OS. In the multivariate analysis, only ASCT remained significant. Bendamustine + rituximab (BR) induction improved the outcomes of non- transplantable patients over R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, steroid). Blastoid morphology and high MIPI were adverse prognostic factors for EFS and OS. Conclusion In the last decade, the outcome of newly diagnosed MCL patients improved. ASCT in the first remission was the main contributor in transplantable patients and BR in non- transplantable. Regularly updated national guidelines may help in a timely adoption of new treatments, thus improving the results.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian medical journal
Brojčani podacivol. 62, br. 5, str. 455-463
p-ISSN0353-9504
DOIhttps://doi.org/10.3325/cmj.2021.62.455-63
URN:NBNurn:nbn:hr:184:936669
Datum objave publikacije2021
URL dokumentahttp://bib.irb.hr/1193971
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Dijeli pod istim uvjetima 4.0 međunarodna (CC BY-SA 4.0)
Datum i vrijeme pohrane2023-02-02 08:03:43